Carrier detection in Duchenne muscular dystrophy.

The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J (1979) 7.55

Carrier detection in Duchenne muscular dystrophy. Evidence from a study of obligatory carriers and mothers of isolated cases. Arch Dis Child (1979) 1.43

Estimation of proportion of new mutants among cases of Duchenne muscular dystrophy. J Med Genet (1978) 1.39

Genetic epidemiology of Lesch-Nyhan disease. Am J Hum Genet (1977) 1.33

The genetic status of mothers of isolated cases of Duchenne muscular dystrophy. J Med Genet (1983) 1.32

Duchenne muscular dystrophy. A population study. Hum Genet (1977) 0.98

Estimation of male to female ratio of mutation rates from carrier-detection tests in X-linked disorders. Am J Hum Genet (1980) 0.90

Electron spin resonance studies of erythrocytes from patients with Duchenne muscular dystrophy. J Clin Invest (1978) 0.89

The female carrier of Duchenne muscular dystrophy. Br Med J (Clin Res Ed) (1982) 0.83

High resolution two-dimensional gel electrophoresis of human erythrocyte membrane proteins. Am J Hum Genet (1982) 0.82

Effect of exercise on serum creatine kinase in carriers of Duchenne muscular dystrophy. J Med Genet (1982) 0.77

The influence of half-chromatid mutations on the ratio of new mutations in lethal X-linked recessive disorders. Am J Hum Genet (1982) 0.77

Genetic counselling in haemophilia by discriminant analysis 1975-1980. J Med Genet (1982) 0.75

Freeze-fracture analysis of intramembrane particles of erythrocytes from normal, dystrophic, and carrier mice. A possible diagnostic tool for detection of carriers of human muscular dystrophy. Am J Pathol (1979) 0.75

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A (1993) 15.04

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 13.80

Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 5.68

Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 4.86

Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 4.85

Detection of deletions spanning the Duchenne muscular dystrophy locus using a tightly linked DNA segment. Nature (1985) 4.62

Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature (1986) 4.13

Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA (1997) 4.00

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J (2006) 3.92

Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. Mol Psychiatry (2008) 3.68

SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am J Hum Genet (2000) 3.58

Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci (1996) 3.26

Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med (1998) 3.23

Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain (1995) 2.99

A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet (1996) 2.98

Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. N Engl J Med (1992) 2.86

Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA (2001) 2.79

Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology (2005) 2.72

Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science (1974) 2.69

Linkage of Charcot-Marie-Tooth neuropathy type 1a to chromosome 17. Exp Neurol (1989) 2.58

Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A (1995) 2.53

The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. JAMA (1997) 2.45

Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA (2001) 2.36

Risk prediction of prevalent diabetes in a Swiss population using a weighted genetic score--the CoLaus Study. Diabetologia (2009) 2.32

An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics (1992) 2.29

Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology (2011) 2.28

Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology (2004) 2.26

Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med (1996) 2.19

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology (2008) 2.17

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology (2003) 2.10

ApoE genotype and survival from intracerebral haemorrhage. Lancet (1995) 2.07

TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry (2008) 2.07

Apolipoprotein E genotype: utility in clinical practice in Alzheimer's disease. J Am Geriatr Soc (1996) 2.03

An alpha-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease. Nat Genet (1999) 2.01

Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology (2001) 2.01

The interaction of a series of hybridoma IgGs with reovirus particles. Demonstration that the core protein lambda 2 is exposed on the particle surface. Virology (1981) 1.98

Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A (1994) 1.91

Linkage of Tunisian autosomal recessive Duchenne-like muscular dystrophy to the pericentromeric region of chromosome 13q. Nat Genet (1992) 1.87

A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann Neurol (1981) 1.75

Identification of novel genes in late-onset Alzheimer's disease. Exp Gerontol (2000) 1.74

Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A (1994) 1.74

Clinical application of apolipoprotein E genotyping to Alzheimer's disease. Lancet (1994) 1.71

Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol (1995) 1.66

Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging (1996) 1.65

Cryptosporidium, enterocytozoon, and cyclospora infections in pediatric and adult patients with diarrhea in Tanzania. Clin Infect Dis (1999) 1.64

Novel polymorphism in the A4 region of the amyloid precursor protein gene in a patient without Alzheimer's disease. Neurology (1993) 1.64

Apolipoprotein E4 allele frequency, ischemic cerebrovascular disease, and Alzheimer's disease. Stroke (1993) 1.63

Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelination. Neuron (1996) 1.58

Isolation and localization of a slow troponin (TnT) gene on chromosome 19 by subtraction hybridization of a cDNA muscle library using myotonic dystrophy muscle cDNA. J Neurosci Res (1990) 1.55

Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest (1994) 1.54

Frontal-lobe mediated behavioral dysfunction in amyotrophic lateral sclerosis. Eur J Neurol (2009) 1.54

Community respiratory viral infection in adult lung transplant recipients. Chest (1998) 1.53

Depressed interferon gamma production and monocyte HLA-DR expression after severe injury. Arch Surg (1988) 1.53

Acetylcholine receptor antibodies in myasthenia gravis. N Engl J Med (1975) 1.52

Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci (2001) 1.52

There is a pathologic relationship between ApoE-epsilon 4 and Alzheimer's disease. Arch Neurol (1995) 1.51

Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol (1993) 1.51

Amyotrophic lateral sclerosis patient antibodies label Ca2+ channel alpha 1 subunit. Ann Neurol (1994) 1.50

Long-term neuromuscular dysfunction produced by passive transfer of amyotrophic lateral sclerosis immunoglobulins. Neurology (1992) 1.49

Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J (2008) 1.48

Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. Ann Thorac Surg (1997) 1.48

Localization of cloned unique DNA to three different regions of chromosome 19: screen for linkage probes for myotonic dystrophy. J Neurogenet (1985) 1.48

Linkage of a locus (CMT4A) for autosomal recessive Charcot-Marie-Tooth disease to chromosome 8q. Hum Mol Genet (1993) 1.47

Direct measurement of hole transport dynamics in DNA. Nature (2000) 1.46

Rapid brain autopsy. The Joseph and Kathleen Bryan Alzheimer's Disease Research Center experience. Arch Pathol Lab Med (1997) 1.46

No genetic effect of alpha1-antichymotrypsin in Alzheimer disease. Genomics (1996) 1.45

Risk of intracranial aneurysms in families with subarachnoid hemorrhage. Can J Neurol Sci (1995) 1.43

Detection of intraabdominal abscess by serum lysozyme estimation. Surgery (1994) 1.43

Eruptive pseudoangiomatosis: a unique childhood exanthem? J Am Acad Dermatol (1993) 1.41

Apolipoprotein E in Creutzfeldt-Jacob disease. Lancet (1995) 1.41

Identification of human T cell leukemia virus in a Japanese patient with adult T cell leukemia and cutaneous lymphomatous vasculitis. Proc Natl Acad Sci U S A (1983) 1.41

Analysis of association at single nucleotide polymorphisms in the APOE region. Genomics (2000) 1.40

The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol (1994) 1.40

The Lambert-Eaton syndrome. Hosp Pract (Off Ed) (1992) 1.39

Accelerated degradation of acetylcholine receptor from cultured rat myotubes with myasthenia gravis sera and globulins. Proc Natl Acad Sci U S A (1977) 1.39

Presenilin-1 polymorphism and Alzheimer's disease. Lancet (1996) 1.38

Patent income. Science (1998) 1.38

Effect of diphenylhydantoin on synaptosome sodium-potassium-ATPase. J Clin Invest (1968) 1.37

Degradation of 14C-labeled streptococcal cell walls by egg white lysozyme and lysosomal enzymes. Infect Immun (1976) 1.36

Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. Neurobiol Dis (1996) 1.35

IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol (1990) 1.35

Localization of Charcot-Marie-Tooth disease type 1a (CMT1A) to chromosome 17p11.2. Genomics (1991) 1.35

Trichodysplasia spinulosa--a newly described folliculocentric viral infection in an immunocompromised host. J Investig Dermatol Symp Proc (1999) 1.33

Enhanced green fluorescent protein as a marker for localizing murine cytomegalovirus in acute and latent infection. J Virol Methods (2000) 1.33

The genetic status of mothers of isolated cases of Duchenne muscular dystrophy. J Med Genet (1983) 1.32

A novel N18TG2 x mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin. J Neurosci (1992) 1.30

Localization of a gene (CMT2A) for autosomal dominant Charcot-Marie-Tooth disease type 2 to chromosome 1p and evidence of genetic heterogeneity. Genomics (1993) 1.29

Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci (1995) 1.29

Biochemical studies of synapses in vitro. I. Protein synthesis. Biochemistry (1968) 1.27

X-linked neuropathy: gene localization with DNA probes. Ann Neurol (1986) 1.27

Clinical and genetic investigation in autosomal dominant limb-girdle muscular dystrophy. Neurology (1988) 1.26

Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: potential genetic and phenotypic heterogeneity. Am J Hum Genet (2000) 1.26

Six-year retrospective surveillance of gastroenteritis viruses identified at ten electron microscopy centers in the United States and Canada. Pediatr Infect Dis J (1990) 1.25

Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype. Neurology (1997) 1.24

Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry (2006) 1.24

Hereditary motor and sensory neuropathy, X-linked: a half century follow-up. Neurology (1987) 1.23

Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. J Neuropathol Exp Neurol (1994) 1.22

Apolipoprotein E and the CNS response to injury. J Cereb Blood Flow Metab (1998) 1.22

Interaction of myasthenic serum globulin with the acetylcholine receptor. Biochim Biophys Acta (1975) 1.21